Recludix Pharma

Recludix is a leader in developing platform approaches to discover effective and selective inhibitors for challenging protein targets. Our platform approach integrates custom-generated DNA-encoded libraries, large-scale parallel assays of structure-activity relationships, and proprietary screening tools to ensure selectivity. Recludix first applied this platform approach to develop SH2 domain inhibitors for the treatment of cancer and inflammatory diseases. For over 30 years, SH2 domains have been recognized as playing a critical role in disease signaling pathways. Recludix has developed a novel SH2-focused platform that integrates new chemical methods and technologies, including a customized SH2 domain library and analyses, to develop precise small-molecule drugs.